Literature DB >> 8360325

Gangliosides and bacterial toxins in Guillain-Barré syndrome.

H J Willison1, P G Kennedy.   

Abstract

Autoimmune factors are strongly favoured as mediating Guillain-Barré syndrome (GBS); however, the precise mechanisms by which this occurs remain unknown. Microbial infections in a susceptible host resulting in an idiosyncratic immune response which cross-reacts with nerve constituents still remains the most plausible working hypothesis on which much current research is based. Considerable recent evidence indicates that this humoral immune response is at least in part directed to gangliosides. Interestingly, many bacterial toxins, including botulinum and tetanus neurotoxins, also bind to gangliosides and induce diseases with some similarities to GBS. This article discusses the evidence in favour of a pathogenic role for anti-ganglioside antibodies in GBS in the context of our knowledge of the biology of gangliosides and the factors that determine their immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360325     DOI: 10.1016/0165-5728(93)90239-u

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Antiglycolipid antibodies in peripheral neuropathy: fact or fiction?

Authors:  H J Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 4.  Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective.

Authors:  Graham M O'Hanlon; Roland W M Bullens; Jaap J Plomp; Hugh J Willison
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

5.  Anti-GT1a IgG in Guillain-Barré syndrome.

Authors:  M Koga; H Yoshino; M Morimatsu; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

6.  Development of an immunoassay for rapid detection of ganglioside GM(1) mimicry in Campylobacter jejuni strains.

Authors:  M M Prendergast; T U Kosunen; A P Moran
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18.

Authors:  H J Willison; G M O'Hanlon; G Paterson; J Veitch; G Wilson; M Roberts; T Tang; A Vincent
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

8.  A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome.

Authors:  R Louwen; D Horst-Kreft; A G de Boer; L van der Graaf; G de Knegt; M Hamersma; A P Heikema; A R Timms; B C Jacobs; J A Wagenaar; H P Endtz; J van der Oost; J M Wells; E E S Nieuwenhuis; A H M van Vliet; P T J Willemsen; P van Baarlen; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-04       Impact factor: 3.267

9.  Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.

Authors:  M M Prendergast; A J Lastovica; A P Moran
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

10.  Myelin- and microbe-specific antibodies in Guillain-Barré syndrome.

Authors:  J Terryberry; M Sutjita; Y Shoenfeld; B Gilburd; D Tanne; M Lorber; I Alosachie; N Barka; H C Lin; P Youinou
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.